Clinical assessment of the efficacy of anti-cancer treatment: current status and perspectives.
With continued enhancements in cancer diagnosis and treatment, clinical assessments are deeper. More composite indicators are applied and evaluations are more "patient-centered", focusing on disease status and response to treatment, as well as the quality-of-life of patients as primary components, including the patients themselves, clinical staff, caregivers, and medical examinations, and other aspects of the evaluation. We reviewed the current research on the application and development of clinical assessment indicators for traditional Chinese medicine (TCM) and modern medicine, and explored its significance and the advancements in effective evaluations.
Zhang
Jing-Jing
JJ
School of Public Health, Kunming Medical University, Kunming, Yunnan, 650031, P.R. China. wanchh@ hotmail.com.
Meng
Qiong
Q
Chang
Wei
W
Wan
Chong-Hua
CH
D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism; D018450:Disease Progression; D018572:Disease-Free Survival; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use; D006801:Humans; D008516:Medicine, Chinese Traditional; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011788:Quality of Life; D012074:Remission Induction; D015996:Survival Rate; D016896:Treatment Outcome; D047368:Tumor Burden
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D004365:Drugs, Chinese Herbal